Nicholls SJ - Search Results

1

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.

Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, Linnebjerg H, Ruotolo G, Turner PK, Michael LF. Nicholls SJ, et al. JAMA. 2023 Sep 19;330(11):1042-1053. doi: 10.1001/jama.2023.16503. JAMA. 2023. PMID: 37638695 Free PMC article. Clinical Trial.

2

Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.

Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, Ray KK, Mason D, Kastelein JJP, Cho L, Libby P, Li N, Foody J, Louie MJ, Lincoff AM. Nissen SE, et al. Among authors: nicholls sj. JAMA. 2023 Jul 11;330(2):131-140. doi: 10.1001/jama.2023.9696. JAMA. 2023. PMID: 37354546 Free PMC article.

3

Bempedoic Acid for Primary Prevention of Cardiovascular Events-Reply.

Nissen SE, Nicholls SJ, Lincoff AM. Nissen SE, et al. Among authors: nicholls sj. JAMA. 2023 Nov 7;330(17):1696-1697. doi: 10.1001/jama.2023.17341. JAMA. 2023. PMID: 37934221 No abstract available.

4

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.

Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, Michael LF, Ruotolo G, Gribble G, Navar AM, Nicholls SJ. Nissen SE, et al. Among authors: nicholls sj. JAMA. 2023 Dec 5;330(21):2075-2083. doi: 10.1001/jama.2023.21835. JAMA. 2023. PMID: 37952254 Free PMC article. Clinical Trial.

5

Lepodisiran for Elevated Lipoprotein(a)-Reply.

Nissen SE, Linnebjerg H, Nicholls SJ. Nissen SE, et al. Among authors: nicholls sj. JAMA. 2024 Apr 23;331(16):1417-1418. doi: 10.1001/jama.2024.0848. JAMA. 2024. PMID: 38536166 No abstract available.

6

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial.

Ballantyne CM, Ditmarsch M, Kastelein JJ, Nelson AJ, Kling D, Hsieh A, Curcio DL, Maki KC, Davidson MH, Nicholls SJ. Ballantyne CM, et al. Among authors: nicholls sj. J Clin Lipidol. 2023 Jul-Aug;17(4):491-503. doi: 10.1016/j.jacl.2023.05.098. Epub 2023 Jun 3. J Clin Lipidol. 2023. PMID: 37277261 Free article. Clinical Trial.

7

How Will Our Practice Change After the CLEAR Outcomes Trial?

Abrahams T, Nelson AJ, Nicholls SJ. Abrahams T, et al. Among authors: nicholls sj. Curr Atheroscler Rep. 2024 Mar;26(3):83-89. doi: 10.1007/s11883-024-01188-5. Epub 2024 Jan 31. Curr Atheroscler Rep. 2024. PMID: 38294660 Free PMC article. Review.

8

Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review.

Tan S, Day D, Nicholls SJ, Segelov E. Tan S, et al. Among authors: nicholls sj. JACC CardioOncol. 2022 Dec 20;4(5):579-597. doi: 10.1016/j.jaccao.2022.09.004. eCollection 2022 Dec. JACC CardioOncol. 2022. PMID: 36636451 Free PMC article. Review.

9

Impact of PCSK9 inhibitors on coronary atheroma phenotype following myocardial infarction: insights from intravascular imaging.

Abrahams T, Fujino M, Nelson AJ, Nicholls SJ. Abrahams T, et al. Among authors: nicholls sj. Curr Opin Cardiol. 2023 Nov 1;38(6):504-508. doi: 10.1097/HCO.0000000000001080. Epub 2023 Sep 25. Curr Opin Cardiol. 2023. PMID: 37751373 Review.

10

The Association Between PCSK9 Inhibitor Use and Sepsis: A Systematic Review and Meta-Analysis of 20 Double-Blind, Randomized, Placebo-Controlled Trials.

Zhou Z, Zhang W, Burgner D, Tonkin A, Zhu C, Sun C, Magnussen CG, Ernst ME, Breslin M, Nicholls SJ, Nelson MR. Zhou Z, et al. Among authors: nicholls sj. Am J Med. 2023 Jun;136(6):558-567.e20. doi: 10.1016/j.amjmed.2023.02.025. Epub 2023 Mar 13. Am J Med. 2023. PMID: 36921646

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

611 results

Search Page